BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27684523)

  • 1. QSAR Model of Unbound Brain-to-Plasma Partition Coefficient, K
    Dolgikh E; Watson IA; Desai PV; Sawada GA; Morton S; Jones TM; Raub TJ
    J Chem Inf Model; 2016 Nov; 56(11):2225-2233. PubMed ID: 27684523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
    Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
    Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR model to predict K
    Umemori Y; Handa K; Sakamoto S; Kageyama M; Iijima T
    SAR QSAR Environ Res; 2022 Nov; 33(11):885-897. PubMed ID: 36420623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.
    Kosugi Y; Mizuno K; Santos C; Sato S; Hosea N; Zientek M
    AAPS J; 2021 May; 23(4):72. PubMed ID: 34008121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
    Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH
    Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate prediction of K
    Ma Y; Jiang M; Javeria H; Tian D; Du Z
    Heliyon; 2024 Jan; 10(2):e24304. PubMed ID: 38298681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unbound Brain-to-Plasma Partition Coefficient, K
    Loryan I; Reichel A; Feng B; Bundgaard C; Shaffer C; Kalvass C; Bednarczyk D; Morrison D; Lesuisse D; Hoppe E; Terstappen GC; Fischer H; Di L; Colclough N; Summerfield S; Buckley ST; Maurer TS; Fridén M
    Pharm Res; 2022 Jul; 39(7):1321-1341. PubMed ID: 35411506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability.
    Pettersson M; Hou X; Kuhn M; Wager TT; Kauffman GW; Verhoest PR
    J Med Chem; 2016 Jun; 59(11):5284-96. PubMed ID: 27228214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
    Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
    Cui Y; Lotz R; Rapp H; Klinder K; Himstedt A; Sauer A
    Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31718023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N; Giri N; Pan G; Elmquist WF
    Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
    Summerfield SG; Zhang Y; Liu H
    J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation.
    Varadharajan S; Winiwarter S; Carlsson L; Engkvist O; Anantha A; Kogej T; Fridén M; Stålring J; Chen H
    J Pharm Sci; 2015 Mar; 104(3):1197-206. PubMed ID: 25546343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.